10-Q: Bio-Techne Q1 FY26: Net Earnings Rise Amidst Sales Dip

Bio-Techne Corporation reported a 1% decrease in net sales to $286.6 million for the first quarter of fiscal 2026, yet saw net earnings climb to $38.2 million, driven by improved gross margins and strategic divestitures.

Summary

• Net sales for the first quarter of fiscal 2026 decreased 1% to $286.6 million compared to $289.5 million in the prior year period.
• Organic revenue also decreased 1%, with foreign currency providing a 1% favorable impact and businesses held-for-sale having a 1% unfavorable impact.
• Net earnings increased to $38.2 million, up from $33.6 million in the prior year quarter.
• Diluted earnings per share rose to $0.24 from $0.21.
• Gross margin improved to 65.6% from 63.2% in the prior year, with adjusted gross margin at 70.2% compared to 69.5%.
• Operating income increased to $47.7 million from $40.0 million.
• Cash and cash equivalents decreased to $145.0 million as of September 30, 2025, from $162.2 million at June 30, 2025.
• Long-term debt was reduced by $46.0 million during the quarter to $300.0 million.
• The Exosome Diagnostics business was divested for approximately $15.0 million, including $6.8 million in stock received at closing and a $9.0 million promissory note.
• Restructuring activities are ongoing, with costs expected through fiscal 2027 for manufacturing optimization and through fiscal 2026 for enterprise-wide initiatives, totaling $125k and $597k respectively for the quarter.

Sentiment

Score: 7

Explanation: While net sales saw a slight decline, the company demonstrated strong profitability improvements with increased gross margin, operating income, and net earnings. Strategic restructuring and divestitures are progressing, and the company maintains strong liquidity and a clear plan for future investments and obligations. The decrease in operating cash flow is noted but attributed to timing.

Positives

• Net earnings increased by 13.6% to $38.2 million despite a slight dip in net sales.
• Diluted EPS improved to $0.24 from $0.21.
• Gross margin percentage increased to 65.6% from 63.2%, indicating improved profitability per sale.
• Operating income increased by 19.2% to $47.7 million.
• The Diagnostics and Spatial Biology segment showed 3% organic revenue growth and a significant operating margin improvement to 11.2% from 5.1%, favorably impacted by the Exosome Diagnostics divestiture and productivity initiatives.
• Long-term debt was reduced by $46.0 million during the quarter.
• The company has $700 million available on its revolving line-of-credit, providing strong liquidity.
• Successful divestiture of Exosome Diagnostics business, contributing to a recovery of assets held-for-sale of $6.8 million and an $8.7 million MDxHealth SA stock investment.

Negatives

• Consolidated net sales decreased by 1% to $286.6 million.
• Organic revenue decreased by 1%.
• The Protein Sciences segment experienced a 3% organic revenue decrease and an unfavorable impact on operating margin due to reduced volume leverage.
• Cash and cash equivalents decreased by $17.2 million during the quarter.
• Cash flow from operating activities significantly decreased to $27.6 million from $63.9 million in the prior year, primarily due to timing of cash payments on operating assets and liabilities.
• The effective income tax rate increased to 20.4% from 16.4%.

Risks

• Integration challenges with newly acquired businesses.
• Uncertainty regarding the introduction and market acceptance of new products.
• Exposure to general national and international economic, political, regulatory, and other conditions.
• Increased competition in the biotechnology reagents, instruments, and services markets.
• Reliance on internal manufacturing and potential supply chain challenges.
• Impact of currency exchange rate fluctuations on financial results.
• Challenges in recruiting and retaining qualified personnel.
• Impact of governmental regulation on operations.
• Need for maintenance of intellectual property rights.
• Credit risk and fluctuations in the market value of the company's investment portfolio.
• Potential for unseen delays and expenses related to facility construction and improvements.
• The ultimate cost of accrued litigation could be materially different than current estimates and accruals, potentially having a material adverse impact on consolidated earnings, financial position, and/or cash flows.

Future Outlook

Management expects gross margins to continue to be impacted by the mix of its portfolio growing at different rates and future acquisitions. Capital expenditures for the remainder of fiscal 2026 are projected to be approximately $27 million, financed through available funds and operating cash flow, primarily for increasing capacity to meet expected sales growth. The consolidated income tax rate for the remainder of fiscal 2026 is expected to range from 26% to 30%, excluding discrete items. The company is committed to meeting its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for at least the next 12 months. The acquisition of the remaining 80.1% of Wilson Wolf Corporation is forecasted to occur between fiscal 2026 and fiscal 2028, with an estimated payment of approximately $1 billion plus potential contingent consideration.

Management Comments

• Organic revenue for the quarter ended September 30, 2025 was primarily driven by favorable performance by our Diagnostics and Spatial Biology portfolio offset by volume pressure in our Protein Sciences segment.
• Fluctuations in consolidated gross margin and adjusted gross margin, as a percentage of sales, have primarily resulted from changes in product mix and a reduction in restructuring charges. We expect that, in the future, gross margins will continue to be impacted by the mix of our portfolio growing at different rates as well as future acquisitions.
• The Protein Sciences segment's operating margin was unfavorably impacted by a reduction in volume leverage.
• The Diagnostics and Spatial Biology segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture and productivity initiatives.
• Management expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit.

Industry Context

The company operates in the life sciences community, providing biotechnology reagents, instruments, and services for research and clinical diagnostic markets. Its strategic pillars include growing and leveraging its core business, capitalizing on high-potential markets, market expansion through innovation and acquisition, delivering best-in-class customer experience, and developing people. The slight decline in overall organic revenue, offset by growth in Diagnostics and Spatial Biology, suggests a mixed market environment, potentially reflecting broader trends in research funding or specific market segment dynamics. The ongoing restructuring efforts indicate a focus on operational efficiency and portfolio optimization, common strategies in a competitive and evolving industry.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• No legal proceedings that are reasonably expected to have a material adverse effect on the company's business, results of operations, financial condition, or cash flows as of November 5, 2025.
• A dispute with the former CEO regarding stock options was resolved through binding arbitration in the quarter ended March 31, 2025, resulting in a $37.2 million payment inclusive of interest and legal fees.
• Litigation charges were immaterial for the quarters ended September 30, 2025 and 2024.

Related Party Transactions

• The investment in Wilson Wolf Corporation, where the company holds a 19.9% equity interest and has a forward contract to acquire the remaining 80.1% by December 31, 2027, represents a significant future related party dealing with an estimated payment of approximately $1 billion plus potential contingent consideration.

Stakeholder Impact

• Shareholders: Received cash dividends, potential for future dividends, and the company has an active stock repurchase plan to mitigate dilution. Net earnings and EPS growth are positive for shareholder value.
• Employees: Ongoing restructuring involves employee severance, but also aims to optimize manufacturing and improve productivity, potentially leading to a more stable and efficient workforce long-term. Share-based compensation continues to be a component of employee benefits.
• Customers: The company's focus on innovation, high-quality scientific tools, and market expansion aims to provide better products and services.
• Creditors: Debt reduction and strong available credit indicate a healthy financial position, reducing credit risk.
• Suppliers: Supply chain challenges are noted as a risk, indicating potential impact on supplier relationships or operations.

Next Steps

• Continue to incur costs related to fiscal 2025 manufacturing optimization restructuring actions through fiscal 2027.
• Continue to incur costs related to the Q1 fiscal 2025 enterprise-wide restructuring actions through fiscal 2026.
• Adopt ASU 2023-09 (Improvements to Income Tax Disclosures) in the fourth quarter of fiscal year 2026.
• Adopt ASU 2024-03 (Income Statement Reporting Comprehensive Income—Expense Disaggregation Disclosures) for fiscal 2027.
• Adopt ASU 2025-05 (Financial Instruments—Credit Losses) for fiscal 2027.
• Adopt ASU 2025-06 (Intangibles—Goodwill and Other—Internal-Use Software) for fiscal 2029.
• Make capital expenditures of approximately $27 million for the remainder of fiscal 2026, primarily for increasing capacity.
• Acquire the remaining 80.1% equity interest in Wilson Wolf Corporation on December 31, 2027, or earlier if certain financial milestones are met, with an estimated payment of approximately $1 billion plus potential contingent consideration.
• Pay a $0.08 per share cash dividend on November 28, 2025, to shareholders of record on November 17, 2025.
• Receive four annual installments of $2.5 million from the Exosome Diagnostics buyer, with up to $5.0 million payable in MDxHealth stock, with the promissory note maturing in September 2029.

Key Dates

Recommendation

While Bio-Techne demonstrated strong profitability improvements with increased gross margins and net earnings despite a slight revenue dip, the overall organic revenue decline and significant decrease in operating cash flow warrant a cautious approach. The ongoing restructuring and strategic divestitures are positive for long-term efficiency, and the company maintains robust liquidity. However, the substantial future obligation for the Wilson Wolf acquisition (approximately $1 billion) and the mixed performance across segments suggest a 'Hold' recommendation. Investors should monitor the execution of restructuring, organic growth trends, and the financing strategy for the Wilson Wolf acquisition.

Keywords

Biotechnology, Life Sciences, Reagents, Instruments, Diagnostics, Spatial Biology, Protein Sciences, 10-Q, Financial Results, Earnings, Gross Margin, Restructuring, Divestiture, Exosome Diagnostics, Wilson Wolf, Spear Bio, MDxHealth, Cash Flow, Debt Reduction, Stock Repurchase